PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Nebulized Fentanyl Matches IV Morphine at 15 Minutes in Small ED Trial

★ Editor's Picknebulized fentanylintravenous morphineopioid analgesicsacute painemergency departmentnon-inferiorityrandomized controlled trialmultimodal analgesianon-invasive analgesiaopioid stewardship Pain Management

Background Information

Nebulized fentanyl competes with intravenous morphine for acute pain relief in the ER.

Emergency departments seek effective, non-invasive pain management alternatives to intravenous morphine. Nebulized fentanyl and intravenous morphine showed similar pain reduction at 15 minutes in acute pain patients. Findings suggest nebulized fentanyl is a viable alternative; however, small sample size limits generalizability. Nebulized fentanyl may offer a non-invasive alternative to intravenous morphine in emergency settings.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Preungprasob P, Rojsaengroeng R, Hengrasmee C, Kanokkarnjana P, Changya Y

Citation: Preungprasob P, Rojsaengroeng R, Hengrasmee C, et al. A non-inferiority randomized controlled trial comparing nebulized fentanyl and intravenous morphine for acute pain management in the emergency department. BMC emergency medicine. 2026;26(1). doi:10.1186/s12873-026-01679-5

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.